Vanguard Group Inc Glycomimetics Inc Transaction History

Vanguard Group Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.16 - $0.32 $4,271 - $8,543	-26,698 Reduced 0.99%	2,670,208 $453,000
Q2 2024 Aug 13, 2024	SELL	$0.24 - $3.04 $15,618 - $197,828	-65,075 Reduced 2.36%	2,696,906 $755,000
Q1 2024 May 10, 2024	BUY	$2.55 - $3.49 $867,285 - $1.19 Million	340,112 Added 14.04%	2,761,981 $8.29 Million
Q3 2023 Nov 14, 2023	BUY	$1.29 - $1.73 $138,628 - $185,912	107,464 Added 4.64%	2,421,869 $3.63 Million
Q2 2023 Aug 14, 2023	SELL	$1.21 - $2.08 $177,177 - $304,570	-146,428 Reduced 5.95%	2,314,405 $4.03 Million
Q1 2023 May 15, 2023	BUY	$1.25 - $4.05 $231,400 - $749,736	185,120 Added 8.13%	2,460,833 $3.1 Million
Q4 2022 Feb 10, 2023	BUY	$0.57 - $3.03 $225,891 - $1.2 Million	396,301 Added 21.09%	2,275,713 $6.9 Million
Q3 2022 Nov 14, 2022	BUY	$0.55 - $0.9 $17,957 - $29,385	32,650 Added 1.77%	1,879,412 $1.04 Million
Q2 2022 Aug 12, 2022	BUY	$0.54 - $1.15 $17,171 - $36,568	31,799 Added 1.75%	1,846,762 $1.11 Million
Q1 2022 May 13, 2022	SELL	$1.0 - $1.58 $423,590 - $669,272	-423,590 Reduced 18.92%	1,814,963 $2.07 Million
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.14 $30,903 - $45,926	-21,461 Reduced 0.95%	2,238,553 $3.22 Million
Q3 2021 Nov 12, 2021	SELL	$1.8 - $2.39 $18,797 - $24,958	-10,443 Reduced 0.46%	2,260,014 $4.95 Million
Q2 2021 Aug 13, 2021	BUY	$2.16 - $3.18 $4.9 Million - $7.22 Million	2,270,457 New	2,270,457 $5.27 Million

736K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $823M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.